|
業務類別
|
Biotechnology |
|
業務概覽
|
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases. |
| 公司地址
| 3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA, USA, 30339 |
| 電話號碼
| +1 678 392-3419 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.inhibikase.com |
| 員工數量
| 16 |
| Dr. John Adams, PhD |
Chief Scientific Officer |
-- |
24/02/2025 |
| Dr. Christopher Cabell, F.A.C.C.,M.D.,M.H.S. |
President and Head, Research and Development |
-- |
24/02/2025 |
| Mr. David McIntyre, C.P.A.,L.L.B.,M.B.A. |
Chief Financial Officer and Principal Accounting Officer |
-- |
14/04/2025 |
| Mr. Mark T. Iwicki |
Director and Chief Executive Officer |
-- |
24/02/2025 |
|
|
| Mr. Dennis N. Berman |
Independent Director |
12/05/2025 |
| Mr. Arvind Kush |
Independent Director |
12/05/2025 |
| Mr. David Canner |
Independent Director |
12/05/2025 |
| Mr. Amit D. Munshi |
Chairman of Board |
18/02/2025 |
| Mr. Roberto Bellini |
Director |
18/02/2025 |
| Dr. Roy Freeman, M.D. |
Independent Director |
12/05/2025 |
| Mr. Vincent E. Aurentz |
Director |
24/02/2025 |
| Mr. Mark T. Iwicki |
Director and Chief Executive Officer |
24/02/2025 |
|
|
|
|
